|
Adenocarcinoma
|
0.700 |
Therapeutic
|
group |
CTD_human |
[Experimental study on combination of Ad-p53 with CDDP or As(2)O(3) in human lung adenocarcinoma cell line GLC-82].
|
11798837 |
2000 |
|
Adenocarcinoma
|
0.700 |
Biomarker
|
group |
CTD_human |
[Experimental study on combination of Ad-p53 with CDDP or As(2)O(3) in human lung adenocarcinoma cell line GLC-82].
|
11798837 |
2000 |
|
Adenocarcinoma
|
0.700 |
Biomarker
|
group |
BEFREE |
While PTEN inactivation leads to PC, it is not sufficient for metastasis, the loss of PTEN concurrently with the inactivation of both TP53 and RB1 empower lineage plasticity in PC cells, which substantially promotes PC metastasis and the conversion to PC adenocarcinoma to neuroendocrine PC (NEPC), demonstrating the essential function of TP53 and RB1 in the suppression of PCSCs.
|
30934773 |
2019 |
|
Adenocarcinoma
|
0.700 |
Biomarker
|
group |
BEFREE |
While P53 appears to be wild-type in the NE cells of benign prostate and adenocarcinoma, immunohistochemical studies show that the majority of the NE tumor cells in SCNC are positive for nuclear p53, suggesting that the p53 is mutated.
|
22389383 |
2012 |
|
Adenocarcinoma
|
0.700 |
GeneticVariation
|
group |
BEFREE |
While 9 of 21 adenocarcinomas tested (42.9%) contained a TP53 mutation, none of 24 samples from Barrett's esophagus were mutated.
|
16416221 |
2006 |
|
Adenocarcinoma
|
0.700 |
AlteredExpression
|
group |
BEFREE |
While 30 of 32 (94%) cases in differentiated nonkeratinizing carcinoma (NKC, WHO type 2) and 16 of 17 (94%) cases in undifferentiated carcinoma (UC, WHO type 3) showed EBERs expression, neither five cases of keratinizing squamous cell carcinoma (KSCC, WHO type 1) nor two cases of adenocarcinoma showed EBERs. bcl-2 protein was detected in 50 (89%) cases, but its expression did not depend on expression of LMP1. p53 protein was detected in 31 (55%) cases, and there was a correlation between expression of EBERs and p53 protein (P < 0.05) but not between LMP1 and p53 protein.
|
10231418 |
1999 |
|
Adenocarcinoma
|
0.700 |
GeneticVariation
|
group |
BEFREE |
We studied 51 cervical carcinomas, among them 25 squamous-cell carcinomas (SCC) and 26 cervical adenocarcinomas (AdCa), and 40 vulvar SCC for the presence of HPV and mutant p53.
|
7591279 |
1995 |
|
Adenocarcinoma
|
0.700 |
Biomarker
|
group |
BEFREE |
We show that p53 loss before OIS is permissive for the transition from lung adenoma to adenocarcinoma.
|
28745322 |
2017 |
|
Adenocarcinoma
|
0.700 |
GeneticVariation
|
group |
BEFREE |
We searched for p53 gene mutations in 74 primary cervical adenocarcinomas with known human papillomavirus (HPV) status.
|
9546366 |
1998 |
|
Adenocarcinoma
|
0.700 |
GeneticVariation
|
group |
BEFREE |
We recently reported that TP53 mutations are a common feature of SNC, with an overall frequency of 77%, and they show association to adenocarcinoma and wood-dust exposure [15].
|
20025891 |
2010 |
|
Adenocarcinoma
|
0.700 |
Biomarker
|
group |
BEFREE |
We propose that inactivation of both p53 and Rb genes may promote cell divisions causing telomere shortening in lung cancer as in the two-stage model, while there may be another pathway to overcome both M1 and M2 mechanisms, especially for adenocarcinoma.
|
7898935 |
1995 |
|
Adenocarcinoma
|
0.700 |
AlteredExpression
|
group |
BEFREE |
We investigated the expression patterns of Ki67 and p53 in metastatic pancreatic adenocarcinomas and analyzed their relationship with disease progression-free survival (PFS) and overall survival (OS) in the overall study population and in patients treated with a gemcitabine-containing chemotherapy versus FOLFIRINOX chemotherapy.
|
30187215 |
2019 |
|
Adenocarcinoma
|
0.700 |
GeneticVariation
|
group |
BEFREE |
We identified p53 mutations in 19 (70%) of 27 primary pancreatic adenocarcinomas.
|
8187092 |
1994 |
|
Adenocarcinoma
|
0.700 |
GeneticVariation
|
group |
BEFREE |
We identified 19 K-ras mutations (all adenocarcinomas except for two) and 40 p53 mutations among the 101 cases.
|
9563724 |
1998 |
|
Adenocarcinoma
|
0.700 |
GeneticVariation
|
group |
BEFREE |
We have studied a series of 100 primary colorectal adenocarcinomas by immunohistochemistry with the monoclonal antibody PAb1801, and single-stranded conformation polymorphism (PCR-SSCP, exons 4-8) followed by direct sequencing of shifted bands. p53 Nuclear staining was undetectable (score 0) in 29 of 100 cases.
|
12777996 |
2003 |
|
Adenocarcinoma
|
0.700 |
GeneticVariation
|
group |
BEFREE |
We have studied 61 resected colorectal adenocarcinomas in order to investigate p53 mutations as a prognostic factor for this pathology.
|
9751268 |
1998 |
|
Adenocarcinoma
|
0.700 |
Biomarker
|
group |
BEFREE |
We have previously documented not only epithelial but also stromal genetic instability in ulcerative colitis (UC)-associated lesions, including adenocarcinomas, using microsatellite markers close to the p53 gene on chromosome 17 (Chr.17).
|
18415748 |
2008 |
|
Adenocarcinoma
|
0.700 |
AlteredExpression
|
group |
BEFREE |
We have found that the expression of p53 messenger RNA is growth regulated in human cells following kinetics similar to that previously shown in mouse 3T3 cells, and is increased in the large majority of colon adenocarcinomas in comparison to adjacent normal mucosa and adenoma.
|
3019534 |
1986 |
|
Adenocarcinoma
|
0.700 |
GeneticVariation
|
group |
BEFREE |
We have analyzed K-ras and TP53 mutations in 77 sporadic colorectal adenocarcinomas by means of polymerase chain reaction and sequencing.
|
14758132 |
2004 |
|
Adenocarcinoma
|
0.700 |
GeneticVariation
|
group |
BEFREE |
We found: 5qLOH in 8 of 16 cases (50%), including 1 adenoma, 3 early- and 4 advanced-stage cancers; APC mutations in 2 adenomas and 1 advanced-stage carcinoma; Ki- or N-ras mutations in 3 adenomas and 3 advanced-stage cancers; p53 mutations in 2 early-stage and 7 advanced-stage adenocarcinomas.
|
8903471 |
1996 |
|
Adenocarcinoma
|
0.700 |
AlteredExpression
|
group |
BEFREE |
We found that half (7 of 14) of lung adenocarcinomas with high telomerase activity showed neither TP53 nor RB1 deletion, while all squamous cell carcinomas and SCLCs with high telomerase activity showed loss of heterozygosity of at least one, if not both, of these suppressor oncogenes, indicating that these genetic aberrations are not required in activation of telomerase in a unique subset of adenocarcinoma.
|
17487398 |
2007 |
|
Adenocarcinoma
|
0.700 |
GeneticVariation
|
group |
BEFREE |
We found high levels of P53 in 23 of the 55 specimens (41.8%), similar to the rate of P53 gene mutations observed in general for pulmonary adenocarcinoma, and levels of ERCC1 and RRM1 also showed distributions similar to those reported generally for non-small lung cell cancer (NSCLC).
|
21248763 |
2011 |
|
Adenocarcinoma
|
0.700 |
Biomarker
|
group |
BEFREE |
We found EGFR expression is higher in the squamous cell carcinomas than in adenocarcinomas (p=0.043), and that nuclear p53 staining correlated with lower differentiated squamous tumors (p=0.034).
|
29731995 |
2018 |
|
Adenocarcinoma
|
0.700 |
Biomarker
|
group |
BEFREE |
We find very little evidence for dissemination from oncogenic KRAS-driven hyperplasias or most adenocarcinomas. p53 loss is insufficient to drive dissemination but rather enables rare cancer cells in a small fraction of primary adenocarcinomas to gain alterations that drive dissemination.
|
24740995 |
2014 |
|
Adenocarcinoma
|
0.700 |
Biomarker
|
group |
BEFREE |
We examined the expression pattern of the AID and p53 proteins in 186 gastric adenocarcinomas by immunohistochemistry.
|
18391550 |
2007 |